We are live on ! Find out more
LOAMS

Lombard Odier Asset Management (Switzerland) Portfolio holdings

AUM $2.63B
1-Year Est. Return 31.52%
This Fund
S&P 500
This Quarter Est. Return
+9.01%
1 Year Est. Return
+31.52%
3 Year Est. Return
+98.77%
5 Year Est. Return
+107.98%
10 Year Est. Return
+494.97%
AUM
$1.97B
AUM Growth
+$464M
Cap. Flow
+$324M
Cap. Flow %
16.44%
Top 10 Hldgs %
16.43%
Holding
517
New
127
Increased
265
Reduced
66
Closed
22

Top Buys

Rank Stock Value
1
AMP icon
Ameriprise Financial
AMP
+$25.4M
2
BIIB icon
Biogen
BIIB
+$22.8M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$21.9M
4
INMD icon
InMode
INMD
+$21.2M
5
BNTX icon
BioNTech
BNTX
+$17.7M

Top Sells

Rank Stock Value
1
FUTU icon
Futu Holdings
FUTU
+$23.2M
2
MRNA icon
Moderna
MRNA
+$22.4M
3
SCHW
Charles Schwab
SCHW
+$17.5M
4
NUAN
Nuance Communications, Inc.
NUAN
+$10.5M
5
NTLA icon
Intellia Therapeutics
NTLA
+$9.95M

Sector Composition

Rank Sector Weight
1 Healthcare 50.23%
2 Consumer Discretionary 12.76%
3 Financials 9.78%
4 Technology 6.11%
5 Industrials 3.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
26
Intellia Therapeutics
NTLA
$1.69B
$25.1M 1.27%
155,201
-127,752
-45% -$9.95M
VOYA icon
27
Voya Financial
VOYA
$9.01B
$25M 1.27%
406,414
-5,050
-1% -$332K
APLS
28
DELISTED
Apellis Pharmaceuticals
APLS
$25M 1.27%
395,033
+15,638
+4% +$807K
BC icon
29
Brunswick
BC
$5.21B
$24.9M 1.26%
250,000
+20,000
+9% +$2.04M
MED icon
30
Medifast
MED
$130M
$24.1M 1.22%
85,000
+5,000
+6% +$1.35M
DRNA
31
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$23.7M 1.2%
636,011
+109,953
+21% +$3.37M
CHE icon
32
Chemed
CHE
$7.07B
$23.7M 1.2%
50,000
– –
INMD icon
33
InMode
INMD
$875M
$23.7M 1.2%
+500,000
New +$21.2M
NVAX icon
34
Novavax
NVAX
$1.31B
$23.2M 1.18%
109,423
+43,021
+65% +$7.88M
SCHW
35
Charles Schwab
SCHW
$189B
$22.8M 1.15%
312,521
-247,394
-44% -$17.5M
THO icon
36
Thor Industries
THO
$4.11B
$22.6M 1.15%
200,000
– –
TDOC icon
37
Teladoc Health
TDOC
$1.22B
$22.4M 1.14%
134,919
+97,470
+260% +$15.8M
TRHC
38
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$22.2M 1.13%
443,743
+99,409
+29% +$4.45M
NVTA
39
DELISTED
Invitae Corporation
NVTA
$22.1M 1.12%
656,137
+352,541
+116% +$11.5M
NBIX icon
40
Neurocrine Biosciences
NBIX
$15.9B
$21.1M 1.07%
216,791
+66,927
+45% +$6.41M
BNTX icon
41
BioNTech
BNTX
$23.3B
$21M 1.07%
+93,839
New +$17.7M
IOVA icon
42
Iovance Biotherapeutics
IOVA
$3.05B
$20.5M 1.04%
788,562
+546,666
+226% +$14.2M
ALLO icon
43
Allogene Therapeutics
ALLO
$714M
$20.2M 1.02%
773,562
+236,824
+44% +$6.75M
TXG icon
44
10x Genomics
TXG
$7.52B
$20.2M 1.02%
102,914
+3,853
+4% +$697K
AAPL icon
45
Apple
AAPL
$4.41T
$18.6M 0.94%
135,963
+16,333
+14% +$2.12M
MDRX
46
DELISTED
Veradigm Inc. Common Stock
MDRX
$18.5M 0.94%
997,355
+157,834
+19% +$2.66M
GTHX
47
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$17.9M 0.91%
815,316
+213,725
+36% +$4.75M
IMGN
48
DELISTED
Immunogen Inc
IMGN
$17.5M 0.89%
2,654,838
+805,066
+44% +$5.62M
EDIT icon
49
Editas Medicine
EDIT
$436M
$17.2M 0.87%
303,133
+113,939
+60% +$4.21M
INDA icon
50
iShares MSCI India ETF
INDA
$6.58B
$15.5M 0.79%
351,200
-50,000
-12% -$2.14M
1
2
3 4 5

Similar funds

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
CCM
Cerberus Capital Management New York $2.65B AUM 20.18% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
MAMU
Marathon Asset Management (UK) London, United Kingdom $2.61B AUM 27.14% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s Q2 2021 Portfolio in Review

As of Q2 2021, Lombard Odier Asset Management (Switzerland) held 517 positions worth $1.97B, up 31% from $1.51B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Lombard Odier Asset Management (Switzerland) deployed $324M of net new capital in Q2 2021, opening 127 new positions and adding to 265 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 270,358 shares worth $26.2M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 45% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Moderna, an estimated $22.4M trimmed.

  • Lombard Odier Asset Management (Switzerland)'s largest Q2 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 270,358 shares worth $26.2M.
  • Lombard Odier Asset Management (Switzerland) added most to Ameriprise Financial in Q2 2021, an estimated $25.4M increase.
  • Lombard Odier Asset Management (Switzerland)'s biggest Q2 2021 reduction was Moderna, cutting an estimated $22.4M.
  • Lombard Odier Asset Management (Switzerland) fully exited Futu Holdings in Q2 2021, selling an estimated $23.2M.
  • Lombard Odier Asset Management (Switzerland)'s ten largest holdings make up 16% of its $1.97B portfolio in Q2 2021.
  • Lombard Odier Asset Management (Switzerland) opened 127 new positions and closed 22 in Q2 2021.
  • Lombard Odier Asset Management (Switzerland)'s portfolio value rose 31% quarter-over-quarter to $1.97B.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2021, filed 13 Aug 2021.